JAVIER
CORTES CASTAN
PROFESOR
Weill Cornell Medical College in Qatar
Doha, QatarPublicacións en colaboración con investigadores/as de Weill Cornell Medical College in Qatar (10)
2024
-
A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer
Future Oncology
-
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study
ESMO Open, Vol. 9, Núm. 9
2023
2015
-
Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies[ Breast Cancer Res Treat (2014), 148, 553-561, DOI 10.1007/s10549-014-3144-y]
Breast Cancer Research and Treatment
-
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer
Science Translational Medicine, Vol. 7, Núm. 283
2014
-
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
Breast Cancer Research and Treatment, Vol. 148, Núm. 3, pp. 553-561
-
Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer
Oncologist, Vol. 19, Núm. 4, pp. 318-327
2013
-
Dasatinib plus capecitabine for advanced breast cancer: Safety and efficacy in phase I study CA180004
Clinical Cancer Research, Vol. 19, Núm. 7, pp. 1884-1893
2011
-
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study
The Lancet, Vol. 377, Núm. 9769, pp. 914-923